Lv4
488 积分 2022-11-01 加入
The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience
18小时前
待确认
Reduced CAR T expansion post infusion is associated with poor survival in patients with large B cell lymphoma after two or more therapies
13天前
已完结
Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia—a worthwhile strategy?
21天前
已完结
The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience
21天前
已完结
Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia
21天前
已完结
Phase II Study of Nelarabine (compound 506U78) in Children and Young Adults With Refractory T-Cell Malignancies: A Report From the Children’s Oncology Group
22天前
已关闭
Phase I Study of 506U78 Administered on a Consecutive 5-Day Schedule in Children and Adults With Refractory Hematologic Malignancies
22天前
已完结
Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia
22天前
已完结
Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities
22天前
已完结
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
24天前
已完结
皖公网安备34019202002308
